European Leukemia Trial Registry
Trial: PEGASYS

More Details
Title Pegylated Interferon Alfa-2a Versus Hydroxyurea in PV and ET
Scientific Title Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Short Title PEGASYS
Trialgroup MPN-SG
Type of Trial multicentric, randomized, prospective, open-label, double-group
Disease Myeloproliferative disease(MPD) Polycythaemia vera
Myeloproliferative disease(MPD) Essential Thrombocythaemia
Age >= 18 years
Status No longer recruiting
Start of Recruitment 01.09.2011
Leader Schlenk, Prof. Dr. med., Richard
Contactperson

Coordinating Investigator Germany
Schlenk, Prof. Dr. med., Richard
Tel: +49 (0)731 500-45900
Fax: +49 (0)731 500-45905
Email: richard.schlenk@uniklinik-ulm.de

Shortprotocol Shortprotocol
created 21.05.2013 Johannes Kraus
changed 13.09.2017 Eva-Maria Ableidinger
ELIC European Leukemia Information Center | no responsibility is taken for correctness and completeness of this information | www.leukemia-net.org | elic@leukemia-net.org